Literature DB >> 17038454

Development of new-onset psoriasis while on anti-TNFalpha treatment.

C Matthews, S Rogers, O FitzGerald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17038454      PMCID： PMC1798366          DOI： 10.1136/ard.2005.040576

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.

Authors:  S N Nikas; P V Voulgari; I P Takalou; P Katsimbri; A A Drosos
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 2.  Antimicrobial treatment of psoriasis.

Authors:  R B Skinner; E W Rosenberg; P W Noah
Journal:  Dermatol Clin       Date:  1995-10       Impact factor: 3.478

3.  Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study.

Authors:  L Naldi; L Peli; F Parazzini; C F Carrel
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

Review 4.  Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?

Authors:  H Valdimarsson; B S Baker; I Jónsdóttir; A Powles; L Fry
Journal:  Immunol Today       Date:  1995-03

5.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Authors:  P P Sfikakis; A Iliopoulos; A Elezoglou; C Kittas; A Stratigos
Journal:  Arthritis Rheum       Date:  2005-08

6.  Psoriasis guttate acuta triggered by varicella zoster virus infection.

Authors:  T Ito; F Furukawa
Journal:  Eur J Dermatol       Date:  2000 Apr-May       Impact factor: 3.328

7.  The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases.

Authors:  Ryan P O'Quinn; Jami L Miller
Journal:  Arch Dermatol       Date:  2002-05

8.  Etanercept as monotherapy in patients with psoriasis.

Authors:  Craig L Leonardi; Jerold L Powers; Robert T Matheson; Bernard S Goffe; Ralph Zitnik; Andrea Wang; Alice B Gottlieb
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245
  8 in total
  2 in total

Review 1.  Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.

Authors:  Paul Sator
Journal:  Ther Adv Chronic Dis       Date:  2018-05-22       Impact factor: 5.091

2.  Psoriasis triggered by infliximab in a patient with Behçet's disease.

Authors:  Yuko Kawazoe; Sunao Sugita; Yukiko Yamada; Ai Akino; Keiko Miura; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2012-10-23       Impact factor: 2.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.